Compare OCCI & FATE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | OCCI | FATE |
|---|---|---|
| Founded | N/A | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 120.2M | 125.6M |
| IPO Year | N/A | 2013 |
| Metric | OCCI | FATE |
|---|---|---|
| Price | $3.02 | $1.25 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $4.10 |
| AVG Volume (30 Days) | 237.4K | ★ 1.2M |
| Earning Date | 12-11-2023 | 05-14-2026 |
| Dividend Yield | ★ 24.32% | N/A |
| EPS Growth | N/A | ★ 29.88 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $6,646,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $10.19 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.62 | $0.91 |
| 52 Week High | $6.82 | $1.94 |
| Indicator | OCCI | FATE |
|---|---|---|
| Relative Strength Index (RSI) | 51.34 | 46.34 |
| Support Level | $2.80 | $0.95 |
| Resistance Level | $3.08 | $1.30 |
| Average True Range (ATR) | 0.09 | 0.08 |
| MACD | 0.02 | -0.01 |
| Stochastic Oscillator | 47.92 | 14.89 |
OFS Credit Co Inc is a non-diversified, closed-end management investment company. Its investment objective is to generate current income, with a secondary objective to generate capital appreciation through investment in collateralized loan obligation (CLO) equity and debt securities. The company invests in floating rate credit instruments and other structured credit investments, including collateralized loan obligation (CLO) debt and subordinated (i.e., residual or equity) securities; traditional corporate credit investments, including leveraged loans and high yield bonds; opportunistic credit investments, including stressed and distressed credit situations and long/short credit investments; and other credit-related instruments.
Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. The company is engaged in the development of programmed cellular immunotherapies for cancer and autoimmune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.